Top

Published in:

Open Access 01-10-2013 | Research article

Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency

Authors: Rachel L Atkinson, Wei T Yang, Daniel G Rosen, Melissa D Landis, Helen Wong, Michael T Lewis, Chad J Creighton, Krystal R Sexton, Sue G Hilsenbeck, Aysegul A Sahin, Abenaa M Brewster, Wendy A Woodward, Jenny C Chang

Published in: Breast Cancer Research | Issue 5/2013

Abstract

Introduction

We hypothesized that cells present in normal tissue that bear cancer stem cell markers may represent a cancer cell of origin or a microenvironment primed for tumor development, and that their presence may correlate with the clinically defined subtypes of breast cancer that show increased tumorigenicity and stem cell features.

Methods

Normal tissues sampled at least 5 cm from primary tumors (normal adjacent tissue) were obtained from 61 chemotherapy-naive patients with breast cancer treated with mastectomy. Samples were stained simultaneously with immunofluorescence for CD44/CD49f/CD133/2 stem cell markers. We assessed the association between CD44⁺CD49f⁺CD133/2⁺ staining in normal adjacent tissue and breast cancer receptor subtype (defined by the expression of the estrogen (ER), progesterone (PR), or human epidermal growth factor-2 (Her2) receptors). We also examined the correlation between CD44⁺CD49f⁺CD133/2⁺ immunofluorescence and each of two previously published gene signatures, one derived from stem-cell enriched tissue and one from BRCA mutated tissue expected to have defective DNA repair.

Results

Patients with triple negative breast cancer (ER^–/PR^–/HER2^–) expressed CD44⁺CD49f⁺CD133/2⁺ in 9 of 9 normal adjacent tissue samples compared with 7 of 52 ER⁺ and/or Her2⁺ tumors (P < 0.001). Further, expression of CD44⁺CD49f⁺CD133/2⁺ by normal adjacent tissue correlated positively with a stem cell-derived tumorigenic signature (P <0.001) and inversely with a defective DNA-repair signature (P <0.001).

Conclusion

Normal cells bearing cancer stem cell markers are associated with the triple negative receptor subtype of breast cancer. This study suggests stem cell staining and gene expression signatures from normal breast tissues represent novel tissue-based risk biomarkers for triple negative breast cancer. Validation of these results in additional studies of normal tissue from cancer-free women could lay the foundation for future targeted triple negative breast cancer prevention strategies.

Available only for authorised users

Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA: Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008, 14: 8010-8018. 10.1158/1078-0432.CCR-08-1208.CrossRefPubMed

Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H: Exemestane for breast-cancer prevention in postmenopausal women. New Engl J Med. 2011, 364: 2381-2391. 10.1056/NEJMoa1103507.CrossRefPubMed

Rosen JM, Jordan CT: The increasing complexity of the cancer stem cell paradigm. Science. 2009, 324: 1670-1673. 10.1126/science.1171837.CrossRefPubMedPubMedCentral

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100.CrossRefPubMedPubMedCentral

Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009, 69: 1302-1313. 10.1158/0008-5472.CAN-08-2741.CrossRefPubMedPubMedCentral

Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH, Birnbaum D, Viens P, Wicha MS: Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010, 16: 45-55. 10.1158/1078-0432.CCR-09-1630.CrossRefPubMed

Meyer MJ, Fleming JM, Lin AF, Hussnain SA, Ginsburg E, Vonderhaar BK: CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 2010, 70: 4624-4633. 10.1158/0008-5472.CAN-09-3619.CrossRefPubMedPubMedCentral

Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009, 106: 13820-13825. 10.1073/pnas.0905718106.CrossRefPubMedPubMedCentral

Atkinson RL, Zhang M, Diagaradjane P, Peddibhotla S, Contreras A, Hilsenbeck SG, Woodward WA, Krishnan S, Chang JC, Rosen JM: Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med. 2010, 2: 55ra79-CrossRefPubMedPubMedCentral

10.

Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM: Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008, 68: 4674-4682. 10.1158/0008-5472.CAN-07-6353.CrossRefPubMedPubMedCentral

11.

Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC: DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010, 123: 189-196. 10.1007/s10549-010-0983-z.CrossRefPubMed

12.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295: 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed

13.

Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL: Early onset of breast cancer in a group of British black women. Br J Cancer. 2008, 98: 277-281. 10.1038/sj.bjc.6604174.CrossRefPubMedPubMedCentral

14.

Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008, 109: 123-139. 10.1007/s10549-007-9632-6.CrossRefPubMed

15.

Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L: Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev. 2011, 20: 1883-1891. 10.1158/1055-9965.EPI-11-0465.CrossRefPubMedPubMedCentral

16.

Bocker W, Moll R, Poremba C, Holland R, Van Diest PJ, Dervan P, Burger H, Wai D, Ina Diallo R, Brandt B, Herbst H, Schmidt A, Lerch MM, Buchwallow IB: Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest. 2002, 82: 737-746. 10.1097/01.LAB.0000017371.72714.C5.CrossRefPubMed

17.

Russo J, Balogh G, Mailo D, Russo PA, Heulings R, Russo IH: The genomic signature of breast cancer prevention. Recent Results Cancer Res. 2007, 174: 131-150. 10.1007/978-3-540-37696-5_12.CrossRefPubMed

18.

Russo J, Moral R, Balogh GA, Mailo D, Russo IH: The protective role of pregnancy in breast cancer. Breast Cancer Res. 2005, 7: 131-142. 10.1186/bcr1029.CrossRefPubMedPubMedCentral

19.

Russo J, Russo IH: Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev. 1994, 3: 353-364.PubMed

20.

Wagner KU, Smith GH: Pregnancy and stem cell behavior. J Mammary Gland Biol Neoplasia. 2005, 10: 25-36. 10.1007/s10911-005-2538-1.CrossRefPubMed

21.

Li C, Wong WH: Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 2001, 98: 31-36. 10.1073/pnas.98.1.31.CrossRefPubMed

22.

Zhang M, Atkinson RL, Rosen JM: Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci USA. 2010, 107: 3522-3527. 10.1073/pnas.0910179107.CrossRefPubMedPubMedCentral

23.

The Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature. 2011, 474: 609-615. 10.1038/nature10166.CrossRefPubMedCentral

24.

Bernstein L: Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 2002, 7: 3-15. 10.1023/A:1015714305420.CrossRefPubMed

25.

Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE: Control of mammary stem cell function by steroid hormone signalling. Nature. 2010, 465: 798-802. 10.1038/nature09027.CrossRefPubMed

26.

Britt KL, Kendrick H, Regan JL, Molyneux G, Magnay FA, Ashworth A, Smalley MJ: Pregnancy in the mature adult mouse does not alter the proportion of mammary epithelial stem/progenitor cells. Breast Cancer Res. 2009, 11: R20-10.1186/bcr2245.CrossRefPubMedPubMedCentral

27.

Siwko SK, Dong J, Lewis MT, Liu H, Hilsenbeck SG, Li Y: Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells–implications for pregnancy-induced protection against breast cancer. Stem Cells. 2008, 26: 3205-3209. 10.1634/stemcells.2008-0103.CrossRefPubMedPubMedCentral

28.

Haakensen VD, Lingjaerde OC, Luders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Børresen-Dale AL, Helland A: Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. BMC Med Genomics. 2011, 4: 77-10.1186/1755-8794-4-77.CrossRefPubMedPubMedCentral

29.

O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. New Engl J Med. 2011, 364: 205-214. 10.1056/NEJMoa1011418.CrossRefPubMed

Title: Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency
Authors: Rachel L Atkinson
Wei T Yang
Daniel G Rosen
Melissa D Landis
Helen Wong
Michael T Lewis
Chad J Creighton
Krystal R Sexton
Sue G Hilsenbeck
Aysegul A Sahin
Abenaa M Brewster
Wendy A Woodward
Jenny C Chang
Publication date: 01-10-2013
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 5/2013
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr3471

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2013

Cdc42 overexpression induces hyperbranching in the developing mammary gland by enhancing cell migration

Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development

Association between mammographic density and basal-like and luminal A breast cancer subtypes

Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index

Help us find the cures

Association of CYP2D6metabolizer status with mammographic density change in response to tamoxifen treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer